Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Feb 11;7(1):11.
doi: 10.1186/s40249-018-0386-7.

A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan

Affiliations
Case Reports

A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan

Asad Zia et al. Infect Dis Poverty. .

Abstract

Background: Approximately 10 million people in Pakistan are infected with the hepatitis C virus (HCV). Most patients develop chronic hepatitis, with rare cases of spontaneous clearance. However, little is known about multidrug resistant viral variants in Pakistan.

Findings: This case study describes a 47-year-old male diagnosed with chronic HCV genotype 3a infection in 2003. After an initial diagnosis of viral infection, the patient remained treatment naïve for 5 years. He received two therapy cycles of interferon (IFN) plus ribavirin (RBV) in 2007 and 2010, however, he was non-responsive to the therapy. The patient then received an additional two treatment cycles of pegylated IFN α-2b plus RBV (in 2011 and 2013); he was still non-responsive. In 2016, the patient underwent sofosbuvir plus RBV combination therapy, however, the sustained virological response was still not achieved. The host genetic factor was found to be heterozygous guanine and thymine (GT) and cytosine and thymine (CT) genotypes of rs8099917 and rs12979860 polymorphism of IL28B, respectively. Phylogenetic analysis suggests that the resistant variant belong to an out-group and may require triple therapy.

Conclusions: This is the first case that reports on a HCV-infected individual who was a non-responder to multiple IFN therapies in Pakistan. Further studies are needed to understand multidrug-resistant HCV variants in the Pakistani population.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study has been approved by the departmental ethical committee of Quaid-i-Azam University Islamabad under the number biotech-F-15-657. Informed consent was obtained from the patient before the blood samples were collected.

Consent for publication

Authors have obtained consent from the study participant to report the data without disclosing his identity.

Competing interests

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
a IL-28B polymorphism showing host genotype CT (rs12978960) and TG (rs8099917) in the patient. Line 1: DNA ladder; Line 2: Amplified uncut product of rs12978960; Line 3: CT genotype by RFLP; Line 4: Amplified uncut product of rs8099917; Line 5: GT genotype by Restriction Fragment Length Polymorphism (RFLP). b Chromatogram showing (a) heterozygous G/T (rs8099917) and (b) heterozygous C/T (rs12979860) polymorphism of IL28b
Fig. 2
Fig. 2
Nucleotide sequence-based genotyping of HCV. The resistant variant is labeled as Pk1-RV (GenBank accession no. KY971494) and clustered with genotype 3a reference sequences. The fragment length of target sequence is 353 nucleotides of NS5B gene. Analysis was carried out using 14 reference viral genome sequences. Sequences included genotype 3a (accession no. AB44523, AB44525, AB44527, PP3, PP39, and KPK2); 3b (accession no. AB444466); 3 k (accession no. AB444470); 1a (KPK1, PP5, PP7); and 1b (KPK6, accession no. AB330344, AB330346)

Similar articles

Cited by

References

    1. Echeverría N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. World J Hepatol. 2015;7(6):831–845. doi: 10.4254/wjh.v7.i6.831. - DOI - PMC - PubMed
    1. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–1672. doi: 10.1056/NEJM200012073432301. - DOI - PubMed
    1. Heathcote EJ, Shiffman ML, WGE C, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343(23):1673–1680. doi: 10.1056/NEJM200012073432302. - DOI - PubMed
    1. Trepo C, Habersetzer F, Bailly F, Berby F, Pichoud C, Berthillon P, et al. Interferon therapy for hepatitis C. Antivir Res. 1994;24(2–3):155–163. doi: 10.1016/0166-3542(94)90064-7. - DOI - PubMed
    1. Akram M, Idrees M, Zafar S, Hussain A, Butt S, Afzal S, et al. Effects of host and virus related factors on interferon-α+ ribavirin and pegylated-interferon+ ribavirin treatment outcomes in chronic hepatitis C patients. Virol J. 2011;8:234. doi: 10.1186/1743-422X-8-234. - DOI - PMC - PubMed

Publication types

MeSH terms